

Giuseppe Milone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6147489/publications.pdf>

Version: 2024-02-01

150
papers

4,457
citations

109264

35
h-index

114418

63
g-index

152
all docs

152
docs citations

152
times ranked

5411
citing authors

#	ARTICLE	IF	CITATIONS
1	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2016, 374, 43-53.	13.9	436
2	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2475-2482.	0.8	185
3	Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2011, 29, 3016-3022.	0.8	171
4	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood</i> , 2013, 121, 5055-5063.	0.6	171
5	Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. <i>Blood</i> , 2006, 107, 4177-4181.	0.6	158
6	Treatment of refractory chronic GVHD with rituximab: a GITMO study. <i>Bone Marrow Transplantation</i> , 2007, 40, 273-277.	1.3	152
7	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. <i>Blood</i> , 2010, 115, 3671-3677.	0.6	151
8	Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2013, 121, 440-446.	0.6	143
9	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	5.1	143
10	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , 2015, 50, 282-288.	1.3	142
11	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
12	<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. <i>British Journal of Haematology</i> , 2002, 117, 379-386.	1.2	123
13	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	2.9	103
14	Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. <i>Genes Chromosomes and Cancer</i> , 2002, 33, 93-97.	1.5	92
15	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. <i>Leukemia</i> , 2012, 26, 1091-1097.	3.3	85
16	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study. <i>Annals of Hematology</i> , 2012, 91, 931-939.	0.8	74
17	Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 241-249.	2.0	69
18	Haemato-oncology and burnout: an Italian survey. <i>British Journal of Cancer</i> , 2008, 98, 1046-1052.	2.9	67

#	ARTICLE	IF	CITATIONS
19	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
20	Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. <i>Leukemia Research</i> , 2004, 28, 469-477.	0.4	57
21	Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. <i>British Journal of Haematology</i> , 2014, 164, 113-123.	1.2	55
22	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1463-1471.	0.8	55
23	Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. <i>Bone Marrow Transplantation</i> , 2010, 45, 385-391.	1.3	53
24	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 372-380.	1.3	53
25	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. <i>Leukemia</i> , 2011, 25, 1627-1631.	3.3	51
26	Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age. <i>Cytotherapy</i> , 2007, 9, 348-355.	0.3	50
27	Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. <i>Haematologica</i> , 2013, 98, 172-178.	1.7	50
28	Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. <i>Annals of Hematology</i> , 2015, 94, 1875-1883.	0.8	47
29	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> , 2019, 6, e89-e99.	2.2	47
30	Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. <i>Bone Marrow Transplantation</i> , 2007, 40, 245-249.	1.3	46
31	Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. <i>Mycoses</i> , 2014, 57, 342-350.	1.8	43
32	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 744-751.	2.0	41
33	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	0.8	39
34	G-CSF Alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. <i>Bone Marrow Transplantation</i> , 2003, 31, 747-754.	1.3	38
35	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2006, 91, 837-9.	1.7	38
36	Multidrug resistance mechanisms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 116, 774-780.	1.2	35

#	ARTICLE	IF	CITATIONS
37	Acute Promyelocytic Leukemia during Pregnancy: Report of 3 Cases. International Journal of Hematology, 2004, 79, 31-36.	0.7	34
38	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplantation, 2012, 47, 831-837.	1.3	31
39	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Annals of Hematology, 2015, 94, 1347-1356.	0.8	31
40	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. Biology of Blood and Marrow Transplantation, 2014, 20, 1026-1032.	2.0	28
41	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transplantation, 2018, 53, 461-473.	1.3	28
42	Trisomy 8 in philadelphia chromosome (ph1)-negative cells in the course of ph1-positive chronic myelocytic leukemia. Genes Chromosomes and Cancer, 1992, 4, 269-270.	1.5	27
43	Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. Haematologica, 2017, 102, 2125-2133.	1.7	27
44	Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. BMC Cancer, 2010, 10, 377.	1.1	26
45	Individual Quality Assessment of Autografting by Probability Estimation for Clinical Endpoints: A Prospective Validation Study from the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1670-1676.	2.0	26
46	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplantation, 2016, 51, 1032-1040.	1.3	26
47	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. European Journal of Haematology, 2007, 78, 330-337.	1.1	25
48	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. Stem Cell Research and Therapy, 2015, 6, 64.	2.4	25
49	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2017, 23, 1549-1554.	2.0	25
50	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. Biology of Blood and Marrow Transplantation, 2019, 25, 932-940.	2.0	25
51	A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. European Journal of Haematology, 1996, 56, 7-11.	1.1	21
52	Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leukemia Research, 2011, 35, 899-903.	0.4	20
53	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. Biology of Blood and Marrow Transplantation, 2013, 19, 940-948.	2.0	20
54	Antitumoural activity of a cytotoxic peptide of Lactobacillus casei peptidoglycan and its interaction with mitochondrial-bound hexokinase. Anti-Cancer Drugs, 2016, 27, 609-619.	0.7	20

#	ARTICLE	IF	CITATIONS
55	Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. <i>Journal of Clinical Medicine</i> , 2022, 11, 623.	1.0	20
56	Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Philadelphia TM + Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. <i>Chemotherapy</i> , 2018, 63, 220-224.	0.8	19
57	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	1.2	19
58	The Use of Silicon Elastomer in Maxillofacial Rehabilitation as a Substitute for or in Conjunction With Resins. <i>Journal of Craniofacial Surgery</i> , 2006, 17, 152-162.	0.3	18
59	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1449-1462.	1.4	18
60	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1900-1907.	1.3	18
61	The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. <i>Human Pathology</i> , 2011, 42, 254-268.	1.1	17
62	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 505-510.	1.3	16
63	Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2015, 50, 790-794.	1.3	15
64	Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.. <i>Blood</i> , 2009, 114, 52-52.	0.6	15
65	AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. <i>Bone Marrow Transplantation</i> , 2011, 46, 314-316.	1.3	14
66	Testicular and cutaneous relapse after hematopoietic transplantation in a patient affected with APL. <i>Bone Marrow Transplantation</i> , 1999, 23, 751-751.	1.3	13
67	B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 <i><i>BCR-ABL</i></i> Transcripts: A Case Report. <i>Anticancer Research</i> , 2019, 39, 431-435.	0.5	13
68	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
69	Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. <i>Blood Transfusion</i> , 2013, 11, 94-101.	0.3	13
70	Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 42-48.	0.6	12
71	Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before cell-replete haploidentical transplantation. <i>Transfusion</i> , 2016, 56, 1096-1100.	0.8	11
72	Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment. <i>Experimental Hematology</i> , 2015, 43, 430-438.e1.	0.2	10

#	ARTICLE	IF	CITATIONS
73	Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 253.	1.0	10
74	TREATMENT OF CML BLAST CRISIS WITH LOW DOSE ARA-C. <i>British Journal of Haematology</i> , 1985, 60, 773-774.	1.2	9
75	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
76	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019048.	0.5	9
77	Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopoietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATC). Results from a Prospective, Multicenter Randomized Phase III Trial (ATCfamilystudy). <i>Blood</i> , 2014, 124, 37-37.	0.6	9
78	CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure. <i>Bone Marrow Transplantation</i> , 2005, 35, 521-522.	1.3	8
79	Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 24-32.	1.3	8
80	The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Societ� Italiana di Emaferesi e Manipolazione Cellulare (SidEM) survey. <i>Transfusion and Apheresis Science</i> , 2013, 49, 615-622.	0.5	8
81	A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. <i>Bone Marrow Transplantation</i> , 2014, 49, 376-381.	1.3	8
82	Chemotherapy-based versus chemotherapy-free stem cell mobilization (�± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 1876-1887.	1.3	8
83	Unusual onset of severe varicella in adult immunocompromised patients. <i>Annals of Hematology</i> , 1992, 64, 155-156.	0.8	7
84	In Vitro Sensitivity of B-CLL Cells to Fludarabine and Interferons. <i>Leukemia and Lymphoma</i> , 1995, 17, 449-453.	0.6	7
85	Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. <i>Leukemia</i> , 2009, 23, 199-203.	3.3	7
86	�Real-life� report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2018, 53, 58-63.	1.3	7
87	Preliminary Results of a Combined Score Based on sLL2-R� and TIM-3 Levels Assayed Early After Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 3158.	2.2	7
88	The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. <i>Annals of Hematology</i> , 2021, 100, 1743-1753.	0.8	7
89	Alternation of Epirubicin and Mitoxantrone in CHOP-like Regimens Retains Efficacy and Reduces Overall Toxicity in Elderly Patients with High and Intermediate Grade Non-Hodgkin Lymphomas. <i>Leukemia and Lymphoma</i> , 2002, 43, 2319-2324.	0.6	6
90	Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m2plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 1950-1960.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Inv(8)(p23q22) and recombinant derivative in a Sicilian family. <i>Clinical Genetics</i> , 1989, 36, 256-261.	1.0	6
92	Inadvertent transplantation of haematopoietic stem cells carrying constitutional Robertsonian translocation from an apparently normal donor to an AML patient: a case report. <i>Bone Marrow Transplantation</i> , 2011, 46, 1278-1279.	1.3	6
93	Chemosensitivity of nonleukemic clonogenic precursors in AML patients in complete remission: Association with CD34+ mobilization and with disease-free survival. <i>Experimental Hematology</i> , 2012, 40, 35-47.e2.	0.2	6
94	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2020, 55, 2244-2253.	1.3	6
95	Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group. <i>Transplantation</i> , 2021, 105, 686-694.	0.5	6
96	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 497-499.	2.0	5
97	Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 267-270.	1.1	5
98	Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 942.	1.0	5
99	Immunomodulating Treatment in Patients with Aplastic Anemia. <i>New England Journal of Medicine</i> , 1983, 308, 1362-1363.	13.9	4
100	Early occurrence of a thyroid carcinoma in a patient who developed Graves' disease after treatment for Hodgkin's disease. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 869-871.	1.8	4
101	Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1093-7.	1.4	4
102	Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study. <i>Bone Marrow Transplantation</i> , 2018, 53, 291-299.	1.3	4
103	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 406.e1-406.e11.	0.6	4
104	Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial. <i>Blood</i> , 2021, 138, 475-475.	0.6	4
105	Cutaneous vasculitis in non Hodgkin's lymphoma. <i>Haematologica</i> , 1995, 80, 529-31.	1.7	4
106	Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa. <i>Bone Marrow Transplantation</i> , 2014, 49, 1193-1197.	1.3	3
107	Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification. <i>Blood</i> , 2019, 134, 3271-3271.	0.6	3
108	A dermatoglyphic study of a group of Sicilian children with fragile-X syndrome. <i>American Journal of Medical Genetics Part A</i> , 1988, 30, 177-183.	2.4	2

#	ARTICLE	IF	CITATIONS
109	Early Clamping of Umbilical Cord Blood and Foetal CD34 Enrichment. Vienna Clinical Weekly, 2001, 28, 141-144.	0.9	2
110	Umbilical cord blood collection in Cesarean section: a comparison before and after placental delivery. Archives of Gynecology and Obstetrics, 2002, 266, 193-194.	0.8	2
111	In AML patients treated by allogeneic hematopoietic transplantation, CD34+ supermobilization is a negative prognostic factor. Leukemia Research, 2013, 37, 853-854.	0.4	2
112	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. Biology of Blood and Marrow Transplantation, 2019, 25, 1387-1394.	2.0	2
113	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. Blood, 2014, 124, 2526-2526.	0.6	2
114	Leaving previously implanted central venous catheters (ports) in place does not increase morbidity in patients undergoing autologous peripheral stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 131-134.	1.3	1
115	Algorithms for early identification of poor mobilization and for on-demand use of plerixafor in patients mobilized by chemotherapy and granulocyte-colony stimulating factor. Leukemia and Lymphoma, 2014, 55, 725-726.	0.6	1
116	Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy. Chemotherapy, 2019, 64, 110-114.	0.8	1
117	Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost. Leukemia Research Reports, 2020, 14, 100227.	0.2	1
118	Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry. Blood, 2011, 118, 2009-2009.	0.6	1
119	Stem Cell Transplantation Can Provide Durable Disease Control in Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC): A Retrospective Study From the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2011, 118, 3077-3077.	0.6	1
120	Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial. Blood, 2012, 120, 1984-1984.	0.6	1
121	Gvhd-Associated Early Impairment of Marrow Function Is Frequent after Allogeneic Transplantation and Is a Sensitive Biomarker for Prediction of Treatment Related Mortality and of Overall Survival. Blood, 2014, 124, 1160-1160.	0.6	1
122	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood, 2014, 124, 727-727.	0.6	1
123	Unmanipulated Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post Transplant Cyclophosphamide Anti-Gvhd Prophylaxis. Blood, 2016, 128, 3475-3475.	0.6	1
124	CD34+ mobilization and pbsc apheretic harvest in multiple myeloma patients at first mobilization attempt: variability in results among different centers. Drugs and Cell Therapies in Hematology, 2012, 1, 91.	0.1	1
125	Palifermin in high dose chemotherapy and autologous stem cell transplantation reduces infection rate. Drugs and Cell Therapies in Hematology, 2013, 2, 133.	0.1	1
126	Autologous Stem Cell Transplantation Followed by Reduced Intensity Allogeneic Stem Cell Transplantation (Tandem Transplantation) as Treatment for Advanced Resistant Hodgkin's Lymphoma Patients. A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2006, 108, 3044-3044.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.. Blood, 2006, 108, 3158-3158.	0.6	1
128	Low-Dose Cytarabine in Myelodysplastic Syndromes and Acute Leukemia. Acta Haematologica, 1986, 75, 125-126.	0.7	0
129	Reasons to Eliminate Umbilical Cord Blood Units before Cryopreservation. Hematology, 2001, 6, 177-180.	0.7	0
130	Quality assessment of autologous haematopoietic blood progenitor cell grafting. Annals of Hematology, 2015, 94, 705-706.	0.8	0
131	Low content of clonogenic progenitors on day+18 is associated with acute graft-versus-host disease and predicts transplant-related mortality. Experimental Hematology, 2021, 95, 58-67.e4.	0.2	0
132	Stem Cell Transplantation in Acute Myeloid Leukemia. , 0, , .		0
133	Adverse Events after Infusions of Cryopreserved Hematopoietic Stem Cells Depend on Non-Mononuclear Cell in Infused Suspension and on Patient Age.. Blood, 2006, 108, 5244-5244.	0.6	0
134	Palifermin in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation (HSCT): The Italian Early Access Program (EAP).. Blood, 2006, 108, 5236-5236.	0.6	0
135	Failure of CD34+ Mobilization in AML Patients Is Associated to an Abnormally High Chemosensitivity of Non Leukemic CFU-GM.. Blood, 2007, 110, 2849-2849.	0.6	0
136	A Prospective Study on the Feasibility of Related and Unrelated Donor Search and Hematopoietic Cell Transplantation for Adults with Acute Leukemia at 31 European Transplant Centers. Blood, 2008, 112, 2385-2385.	0.6	0
137	The Presence of An Internal Tandem Duplicate of FLT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,. Blood, 2011, 118, 4139-4139.	0.6	0
138	Palifermin In High Dose Chemotherapy and Autologous Stem Cell Transplantation: Reduction of Infections and of Resources Utilization with No Increase in Overall Cost. Blood, 2011, 118, 4568-4568.	0.6	0
139	CD34+ mobilization and pbsc apheretic harvest in multiple myeloma patients at first mobilization attempt: variability in results among different centers. Drugs and Cell Therapies in Hematology, 2012, 1, .	0.1	0
140	Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls?. Blood, 2012, 120, 4094-4094.	0.6	0
141	Palifermin in high dose chemotherapy and autologous stem cell transplantation reduces infection rate. Drugs and Cell Therapies in Hematology, 2013, 2, .	0.1	0
142	Plerixafor On Demand Associated With Chemotherapy and G-CSF: Interim Analysis Of a Prospective Study Shows Significant Improvement In PBSC Mobilization and Harvest With No Increase In Costs. Blood, 2013, 122, 4509-4509.	0.6	0
143	Results and Cost Effectiveness of "on-Demand" Plerixafor Added to Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma. Blood, 2015, 126, 4305-4305.	0.6	0
144	Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS). Blood, 2016, 128, 3473-3473.	0.6	0

#	ARTICLE	IF	CITATIONS
145	High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt. Blood, 2018, 132, 4642-4642.	0.6	0
146	ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience. Blood, 2018, 132, 3381-3381.	0.6	0
147	FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT. Blood, 2018, 132, 609-609.	0.6	0
148	Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens. Blood, 2019, 134, 1974-1974.	0.6	0
149	Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. Blood, 2021, 138, 2849-2849.	0.6	0
150	On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877). Blood, 2020, 136, 13-14.	0.6	0